EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Epidemiology of Adult Soft-Tissue Sarcomas in Germany

Catherine W Saltus iD, Brian Calingaert, Sean Candrilli, Maria Lorenzo, Yulia D'yachkova, Thorsten Otto, Uwe Wagner, James A Kaye

Sarcoma · 2018 · 2018 · 1-11

DOI: 10.1155/2018/5671926 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Sarcoma, 2018. Verfasst von Catherine W Saltus und 7 weiteren Autor:innen. Beteiligte Einrichtung: RTI Health Solutions, 307 Waverly Oaks Rd., Suite 101, Waltham, MA, USA. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Eli Lilly and Company.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We conducted a retrospective cohort study using data compiled from the regional German cancer registries by the Centre for Cancer Registry Data (ZfKD) at the Robert Koch Institut (RKI) to describe the epidemiology of adult soft-tissue sarcomas (STS) in Germany in 2003–2012, focusing on advanced STS. We identified 33,803 incident adult cases of STS (other than the Kaposi sarcoma and gastrointestinal stromal tumors). The incidence of STS was 6.05 (95% confidence interval (CI), 5.82–6.29) per 100,000 in 2012 (4,079 cases). During 2003–2012, the most common histologic categories were leiomyosarcoma (19%), liposarcoma (16%), and STS not otherwise specified (14%). The overall STS-specific mortality rate in 2012 was 2.31 (95% CI, 2.06–2.57) per 100,000, and the median overall survival from initial diagnosis was 5.83 (95% CI, 5.50–6.08) years. Using STS mortality rates as a proxy for incidence of advanced STS in Germany and applying the age- and sex-specific rates to the corresponding German population, we estimated that 1,581 incident adult advanced STS cases occurred in Germany in 2012. Our findings contribute to a refined understanding of the population burden of STS in Germany, including the number of patients with advanced STS who may be candidates for systemic treatment.

Autor:innen und Institutionen

  • RTI Health Solutions, 307 Waverly Oaks Rd., Suite 101, Waltham, MA, USA.
  • RTI Health Solutions, 200 Park Offices Drive, Research Triangle Park, NC, USA.
  • Lilly Research Centre, Eli Lilly and Company Limited, Erl Wood Manor, Sunninghill Road, Windlesham, Surrey GU20 6PH, UK.
  • Eli Lilly GmbH, Koelblgasse 6-8, Vienna 1030, Austria.
  • Lilly Deutschland GmbH, Werner-Reimers-Straße 2-4, 61352 Bad Homburg, Germany.

ORCID-Profile: Catherine W Saltus

Förderung

  • Eli Lilly and Company

Zitieren

APA

Saltus, C. W., Calingaert, B., Candrilli, S., Lorenzo, M., D'yachkova, Y., Otto, T., Wagner, U., & Kaye, J. A. (2018). Epidemiology of Adult Soft-Tissue Sarcomas in Germany. Sarcoma, 2018, 1-11. https://doi.org/10.1155/2018/5671926

Vancouver

Saltus CW, Calingaert B, Candrilli S, Lorenzo M, D'yachkova Y, Otto T, et al. Epidemiology of Adult Soft-Tissue Sarcomas in Germany. Sarcoma. 2018;2018:1-11. doi:10.1155/2018/5671926

BibTeX
@article{Saltus2018,
  author = {Saltus, Catherine W and Calingaert, Brian and Candrilli, Sean and Lorenzo, Maria and D'yachkova, Yulia and Otto, Thorsten and Wagner, Uwe and Kaye, James A},
  title = {Epidemiology of Adult Soft-Tissue Sarcomas in Germany},
  journal = {Sarcoma},
  year = {2018},
  volume = {2018},
  pages = {1--11},
  doi = {10.1155/2018/5671926}
}
Kostenlos starten →